[HTML][HTML] Unleashing NK-and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial
VCM Geurts, L Voorwerk, S Balduzzi, R Salgado… - The Breast, 2023 - Elsevier
The large majority of patients with HER2-positive metastatic breast cancer (MBC) will
eventually develop resistance to anti-HER2 therapy and die of this disease. Despite …
eventually develop resistance to anti-HER2 therapy and die of this disease. Despite …